Drug Pricing
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary
Congress Should Not Impose Foreign Price Controls On Innovative Drugs
Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. ...
Commentary
Medicaid Is Not A Test Lab For Foreign Price Controls
In a desperate bid to claim fiscal discipline without touching entitlements, President Donald J. Trump is pushing congressional Republicans to adopt a “most favored nation” (MFN) drug pricing model for Medicaid. This policy would tie Medicaid reimbursements to the lowest prices paid in other developed countries—countries where government officials dictate ...
Commentary
Delaying Coverage of Weight-loss Meds Won’t Cure Obesity
In an interview this month, Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., appeared open to the idea of Medicare covering drugs like Ozempic and Wegovy for beneficiaries with obesity. “Ideally, over the long term, we’d like to see . . . those drugs available for people after ...
Commentary
Drug company profits don’t threaten lives; price controls do
More than 4 in 5 Americans blame the pharmaceutical industry’s profits for the high prices of prescription drugs. It’s little wonder, then, that roughly the same share supports placing price controls on prescription drugs through Medicare. The logic is straight out of Robin Hood. Our leaders should take from the ...
Commentary
Pharmaceutical Tariffs Will Have Horrific Side Effects
President Trump implemented a raft of tariffs this week. All imports are subject to a 10% import duty. Those from China are subject to a 145% tariff. Pharmaceuticals appear to be exempt from the tariffs — for now. Drug manufacturers expect to get hit with tariffs at some point; they’re ...
Commentary
Price Controls Won’t End Global Pharma Freeloading
A new paper by the America First Policy Institute, a think tank with close ties to the Trump administration, has revived the debate over global drug pricing. The paper points out that patients in the United States tend to pay considerably more for brand-name prescription drugs than those in most ...
Commentary
Here’s How Trump’s Pick To Lead The FDA Can Supercharge The Agency
The U.S. Senate last week confirmed former Johns Hopkins surgeon and professor Dr. Marty Makary to lead the Food and Drug Administration. During his confirmation hearing, Makary said his goals for the agency were “more cures and meaningful treatments for Americans.” Throughout the hearing, he offered insight on how he ...
Blog
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Commentary
The Future of Healthcare Under Donald Trump
On this episode of All Things, Sally Pipes–healthcare aficionado and author of “The World’s Medicine Chest”–lays out the risks of Joe Biden’s coming drug price controls, the need to cut billions in waste and fraud from Medicaid, the fading chances for replacing ObamaCare, and the upsides and downsides of some ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Congress Should Not Impose Foreign Price Controls On Innovative Drugs
Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. ...
Medicaid Is Not A Test Lab For Foreign Price Controls
In a desperate bid to claim fiscal discipline without touching entitlements, President Donald J. Trump is pushing congressional Republicans to adopt a “most favored nation” (MFN) drug pricing model for Medicaid. This policy would tie Medicaid reimbursements to the lowest prices paid in other developed countries—countries where government officials dictate ...
Delaying Coverage of Weight-loss Meds Won’t Cure Obesity
In an interview this month, Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., appeared open to the idea of Medicare covering drugs like Ozempic and Wegovy for beneficiaries with obesity. “Ideally, over the long term, we’d like to see . . . those drugs available for people after ...
Drug company profits don’t threaten lives; price controls do
More than 4 in 5 Americans blame the pharmaceutical industry’s profits for the high prices of prescription drugs. It’s little wonder, then, that roughly the same share supports placing price controls on prescription drugs through Medicare. The logic is straight out of Robin Hood. Our leaders should take from the ...
Pharmaceutical Tariffs Will Have Horrific Side Effects
President Trump implemented a raft of tariffs this week. All imports are subject to a 10% import duty. Those from China are subject to a 145% tariff. Pharmaceuticals appear to be exempt from the tariffs — for now. Drug manufacturers expect to get hit with tariffs at some point; they’re ...
Price Controls Won’t End Global Pharma Freeloading
A new paper by the America First Policy Institute, a think tank with close ties to the Trump administration, has revived the debate over global drug pricing. The paper points out that patients in the United States tend to pay considerably more for brand-name prescription drugs than those in most ...
Here’s How Trump’s Pick To Lead The FDA Can Supercharge The Agency
The U.S. Senate last week confirmed former Johns Hopkins surgeon and professor Dr. Marty Makary to lead the Food and Drug Administration. During his confirmation hearing, Makary said his goals for the agency were “more cures and meaningful treatments for Americans.” Throughout the hearing, he offered insight on how he ...
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
The Future of Healthcare Under Donald Trump
On this episode of All Things, Sally Pipes–healthcare aficionado and author of “The World’s Medicine Chest”–lays out the risks of Joe Biden’s coming drug price controls, the need to cut billions in waste and fraud from Medicaid, the fading chances for replacing ObamaCare, and the upsides and downsides of some ...
